WO2013168032A1 - Compositions pharmaceutiques contenant de la rasagiline - Google Patents

Compositions pharmaceutiques contenant de la rasagiline Download PDF

Info

Publication number
WO2013168032A1
WO2013168032A1 PCT/IB2013/053060 IB2013053060W WO2013168032A1 WO 2013168032 A1 WO2013168032 A1 WO 2013168032A1 IB 2013053060 W IB2013053060 W IB 2013053060W WO 2013168032 A1 WO2013168032 A1 WO 2013168032A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
rasagiline
salt
pharmaceutical composition
acid
Prior art date
Application number
PCT/IB2013/053060
Other languages
English (en)
Inventor
Pradeep G. Surve
Pankaj S. Mandpe
Subhash KALE
Tejas VASHI
Rajesh J. KASUNDE
Original Assignee
Micro Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micro Labs Limited filed Critical Micro Labs Limited
Publication of WO2013168032A1 publication Critical patent/WO2013168032A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Definitions

  • the present invention relates to stable oral pharmaceutical compositions comprising Rasagiline or a pharmaceutically acceptable salt thereof with at least one or more pharmaceutically acceptable antioxidant(s), wherein the said composition is free of sugar alcohols.
  • the present invention also provides process for the preparation of such compositions which are used for the treatment of Parkinson's disease, memory disorders and dementia of the Alzheimer type (DAT), depression and hyperactive syndrome in children or a disease or condition associated with these, optionally with one or more pharmaceutically acceptable excipient(s).
  • Rasagiline is a propargylamine-based drug which is a selective irreversible inhibitor of the enzyme monoamine oxidase (hereinafter MAO) and provides the R(+) enantiomer of N-propargyl- 1 -aminoindan which is a selective irreversible inhibitor of the B-form of monoamine oxidase enzyme (hereinafter MAO-B).
  • MAO monoamine oxidase
  • MAO-B B-form of monoamine oxidase enzyme
  • Rasagiline is used as a monotherapy in early Parkinson's disease or as an adjunct therapy with levodopa.
  • Rasagiline is currently administered orally in the form of a conventional tablet and is presently marketed in US as Azilect® by Teva Pharma.
  • the drug compound having the adopted name "Rasagiline mesylate” has chemical names (1 R)-N-prop-2-ynyl- 2,3-dihydro-l H-inden-1 -amine methanesulfonate; or 1 H-inden-1 -amine, 2,3- dihydro-N-2-propynyl-, (1 R)-, methanesulfonate; and has structural formula as below.
  • US Patent no. 5,387,612 and 5,453,446 relate to methods of treating Parkinson's disease using Rasagiline or a pharmaceutically acceptable salt.
  • US Patent No. 6, 126,968 assigned to Teva Pharmaceuticals discloses a pharmaceutical formulation comprising Rasagiline or a pharmaceutically acceptable salt thereof and at least one alcohol selected from the group consisting of pentahydric and hexahydric alcohols. According to the patent, the presence of certain alcohols significantly improves stability of pharmaceutical formulations of Rasagiline or its pharmaceutically acceptable salts. Formulations disclosed include alcohols selected from mannitol, xylitol and sorbitol.
  • US application No. US20100189791 discloses a stable oral dosage form comprising a core having Rasagiline malate and at least one pharmaceutically acceptable excipient; and an acid resistant pharmaceutically acceptable coating.
  • US application no US20100189790 discloses a stable oral dosage form comprising a core having a production process-resulting form of Rasagiline and at least one pharmaceutically acceptable excipient; and an acid resistant pharmaceutically acceptable coating, the production process comprising a) preparing the core by admixing Rasagiline base, citric acid and/or malic acid, and a pharmaceutically acceptable excipient; and b) coating the core with the acid resistant pharmaceutically acceptable coating.
  • WO201 1010324 discloses a stable oral pharmaceutical composition
  • a pharmaceutically acceptable carrier selected from a polyhydric alcohol, disaccharide(s) and polysaccharide(s) or mixtures thereof, and wherein the said composition is free of pentahydric or hexahydric alcohols.
  • WO20101 1 1264 discloses a pharmaceutical composition
  • a pharmaceutical composition comprising Rasagiline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the composition: is free from sugar alcohols; and has content uniformity from about 90% to about 1 10% of the label content of Rasagiline or its pharmaceutically acceptable salt and a relative standard deviation not more than about 5%.
  • International publication no WO2010070090 discloses a solid composition comprising at least one pharmaceutically acceptable excipient and as an active ingredient Rasagiline or a pharmaceutically acceptable salt thereof, characterized in that auxiliary and active substance is present in a homogeneous, molecularly disperse mixture.
  • International publication No WO201 1050728 discloses a stable Rasagiline composition containing acceptable salt of Rasagiline or drugs and drug acceptable antioxidants. It further discloses the composition specifically used for transdermal or mucosal administration.
  • the inventors of the present invention with considerable expense of intellectual effort have done extensive research and conducted several experiments to develop a stable pharmaceutical composition of Rasagiline or a pharmaceutically acceptable salt thereof without using sugar alcohol.
  • the present invention also provides safe and effective compositions for the management of Parkinson's disease which are particularly devoid of the associated side effects and therefore provides a significant advancement in the said field.
  • It is an objective of the present invention to provide a stable oral pharmaceutical composition comprising Rasagiline or its pharmaceutically acceptable salt thereof with at least one pharmaceutically acceptable antioxidant(s) and optionally with one or more pharmaceutically acceptable excipient(s), wherein the said composition is free of sugar alcohols.
  • It is an objective of the present invention to provide a stable oral pharmaceutical composition comprising Rasagiline mesylate with at least one pharmaceutically acceptable antioxidant(s) and optionally with one or more pharmaceutically acceptable excipient(s), wherein the said composition is free of sugar alcohols.
  • Rasagiline mesylate with at least one pharmaceutically acceptable antioxidant(s) selected from the group, but not limited to, of ascorbic acid and their esters, alpha-tocopherol, ethylenediaminetetraacetic acid, sodium metabisulfite, sodium bisulfite, Butylated Hydroxy Toluene (BHT), Hydroxy propyl ⁇ -cyclodextrin, ⁇ -cyclodextrin, Propyl gallate, Butylated Hydroxy Anisole (BHA), fumaric acid or its salt, propionic acid or its salt, erythorbic acid or its salt, citric acid or its salt and tartaric acid or its salt and the like, optionally with one or more pharmaceutically acceptable excipient(s).
  • antioxidant(s) selected from the group, but not limited to, of ascorbic acid and their esters, alpha-tocopherol, ethylenediaminetetraacetic acid, sodium metabisulfite, sodium bisulfite, Butylated
  • composition is devoid of any sugar alcohols, i.e., pentahydric alcohols or hexahydric alcohols or polyhydric alcohols.
  • compositions that are formulated as, but not limited to, tablets, pellets, capsules, suspensions, syrups, sachets, optionally with one or more pharmaceutically acceptable excipient(s).
  • oral tablet composition which can be given either as immediate release, sustained release, extended release, delayed release or in combination thereof.
  • the process for preparing a stable oral pharmaceutical composition comprising Rasagiline or its pharmaceutically acceptable salt with at least one pharmaceutically acceptable antioxidant(s), and pharmaceutically acceptable carriers, wherein the said composition is free of sugar alcohols, comprises the steps of:
  • step a) preparing a binder solution by adding Rasagiline or its pharmaceutically acceptable salt, anti oxidant and water under constant stirring, b) adding the binder solution of step a) to a dry mix of other pharmaceutically acceptable carriers to prepare granules,
  • compositions of the present invention provide effective prophylactic or therapeutic concentrations of active agent(s) for immediate release of the composition.
  • the present invention provides pharmaceutical formulations comprising Rasagiline or a salt thereof, which are used for the management of diseases or disorders, comprising administering a formulation containing an effective amount of the active agent.
  • Rasagiline is in the form of its mesylate salt.
  • Rasagiline in the form of the free base, in the form of a pharmaceutically acceptable salt thereof, or any isomer, derivative, hydrate, solvate, or pro drug thereof.
  • the present invention provides a stable oral pharmaceutical composition
  • a stable oral pharmaceutical composition comprising Rasagiline or its pharmaceutically acceptable salt thereof and optionally one or more pharmaceutically acceptable excipient(s), wherein the said composition is free of sugar alcohols.
  • 'stable' refers to chemical stability of Rasagiline or its salts in solid dosage forms wherein there is no significant change in impurities percentages and dissolution profile, when kept at accelerated temperature and humidity conditions. It would be noteworthy that prior arts relate to pharmaceutical compositions of Rasagiline and its salts, incorporating relatively large amount of sugar alcohols to improve the stability of formulation. Sugar alcohols specifically mannitol, xylitol and sorbitol in an amount of at least 70% by weight of the composition are being used for this purpose. However, these compositions may further comprise acids for added advantages w.r.t. stability of the compositions.
  • stable oral pharmaceutical composition comprises Rasagiline mesylate with at least one pharmaceutically acceptable antioxidant(s) and optionally one or more pharmaceutically acceptable excipient(s), wherein the said composition is free of sugar alcohols.
  • Inventor of the instant invention surprisingly found that oral pharmaceutical compositions of Rasagiline mesylate are equally stable by using only antioxidants, without using any added sugar alcohols, as used in commercially available innovator formulation.
  • the amount of Rasagiline and/or Rasagiline mesylate used in the formulation is up to 5% of the total weight of the composition.
  • the antioxidant(s) used in the invention are selected from the group, but not limited to, ascorbic acid and their esters, alpha- tocopherol, ethylenediaminetetraacetic acid, sodium metabisulfite, sodium bisulfite, Butylated Hydroxy Toluene (BHT), Hydroxy propyl ⁇ -cyclodextrin, ⁇ -cyclodextrin, Propyl gallate, Butylated Hydroxy Anisole (BHA), fumaric acid or its salt, propionic acid or its salt, erythorbic acid or its salt, citric acid or its salt and tartaric acid or its salt and the like.
  • the amount of antioxidant used in the invention is from 0.1 to 5% of total weight of the composition. In preferred embodiments, the amount of antioxidant is from 0.1 to 2% of the total weight of the composition.
  • the present invention specifically uses the antioxidant ascorbic acid esters or ascorbic acid and/or citric acid, either alone or in combination thereof.
  • the particle sizes of Rasagiline mesylate are adequate to maintain acceptable content uniformity of the blend that is used to make the pharmaceutical compositions of the present invention.
  • the present invention includes stable formulations comprising Rasagiline mesylate and at least one pharmaceutically acceptable carrier, wherein any Rasagiline-related impurities, such as degradants formed during processing or storage, are not present or are well within the prescribed limits.
  • the present invention uses active ingredient in binder solution, which in turn nullifies the influence of particle size on the in-vitro performance of the formulation.
  • the pharmaceutical compositions can be formulated as, but not limited to tablets, pellets, capsules, suspensions, syrups, sachets.
  • the present invention provides oral tablet composition which can be given either as immediate release, sustained release, extended release, delayed release or in combination thereof.
  • the composition is specifically formulated as tablet dosage form.
  • the pharmaceutically acceptable excipient(s) of the present invention are selected from, but not limited to, a group comprising diluents, lubricants, binders, surfactants, anti-oxidants, colorants, glidants, complexing agents and the like, known in the art, used either alone or in combination thereof.
  • Suitable diluents include for example pharmaceutically acceptable inert fillers such as microcrystalline cellulose, lactose, starch, dibasic calcium phosphate, saccharides, and/or mixtures of the foregoing.
  • diluents include microcrystalline celluloses such as Avicel® PHI 01, Avicel® PHI 02, Avicel® PHI 12, Avicel® PH200, Avicel® PH301 and Avicel® PH302; lactose such as lactose monohydrate, lactose anhydrous and Pharmatose® DCL21, including anhydrous, monohydrate and spray dried forms; dibasic calcium phosphate such as Emcompress®; starch; sucrose; glucose, and the like used either alone or in combination thereof.
  • Suitable lubricants are selected from but not limited to a group comprising talc; stearic acid, magnesium stearate, calcium stearate, colloidal silicon dioxide such as Aerosil® 200; sodium stearyl fumarate, hydrogenated vegetable oil and the like used either alone or in combination thereof.
  • Suitable binder useful in the present invention is selected from but not limited to a group comprising polyvinylpyrrolidone (e.g. PVP K-90 or PVP K-30), copovidone (e.g. Plasdone® S630), cellulosic polymers (e.g. hydroxypropyl cellulose, hydroxypropylmethyl cellulose, or the like), gums such as xanthan, alginates such as sodium alginate, polyvinylacetate, and the like used either alone or in combination thereof. More preferably, copovidone (e.g. Plasdone® S630) is useful as a binder.
  • polyvinylpyrrolidone e.g. PVP K-90 or PVP K-30
  • copovidone e.g. Plasdone® S630
  • cellulosic polymers e.g. hydroxypropyl cellulose, hydroxypropylmethyl cellulose, or the like
  • gums such as xanthan
  • alginates
  • Suitable antioxidant is selected from but not limited to a group comprising ascorbic acid and their esters, alpha-tocopherol, ethylenediaminetetraacetic acid, sodium metabisulfite, sodium bisulfite, Butylated Hydroxy Toluene (BHT), Hydroxy propyl ⁇ -cyclodextrin, ⁇ -cyclodextrin, Propyl gallate, Butylated Hydroxy Anisole (BHA), fumaric acid or its salt, propionic acid or its salt, erythorbic acid or its salt, citric acid or its salt and tartaric acid or its salt and the like.
  • BHT Butylated Hydroxy Toluene
  • BHA Butylated Hydroxy Anisole
  • fumaric acid or its salt propionic acid or its salt
  • erythorbic acid or its salt citric acid or its salt and tartaric acid or its salt and the like.
  • Suitable glidant is selected from but not limited to a group comprising talc, magnesium stearate, stearic acid, calcium stearate or hydrogenated castor oil and the like, used either alone or in combination thereof.
  • the present invention provides pharmaceutical formulations of Rasagiline or its salt which is used for the management of Parkinson's disease, memory disorders and dementia of the Alzheimer type (DAT), depression and hyperactive syndrome in children or a disease or condition associated with these by administering a formulation containing an effective amount of Rasagiline or a pharmaceutically acceptable salt thereof.
  • the present invention provides pharmaceutical formulations of Rasagiline or its salt which are used for the management of Parkinson's disease or disorders either alone as a monotherapy as well as adjunct therapy with levodopa.
  • the present invention also provides processes for preparation of the formulations/compositions of Rasagiline or its salts.
  • the process comprises the following steps:
  • Desired amount of diluents are weighed, passed through suitable mesh size and mixed for specified time to obtain a dry mix.
  • Binder solution is prepared by adding active ingredient, anti oxidant and water under constant stirring.
  • Binder solution of step ii) is added to dry mix of step i) in a granulator to obtain granules.
  • step iii) Granules of step iii) are dried to obtain the desired LOD.
  • step iv) Dried Granules of step iv) are prelubricated with suitable lubricants and glidants. vi) Granules of step v) are used to prepare the final desired formulation.
  • Table 1 represents t le % total impurity of different compositions under accelerated temperature and humidity conditions. It is noteworthy that, during initial and stability period, the composition of Example 1 (without having sugar alcohol) has significantly decreased % total impurity formed when compared to the composition of Example 2 (with sugar alcohols) and the Innovator formulation. This % limits are within the specification range and shows composition is stable through out the period.
  • Table-2 Pharmaceutical composition of the invention (Rasagiline mesylate Tablet):
  • step ii) Sifted material of step i) were mixed in RMG for 10 minutes at slow speed.
  • Binder solution was prepared by adding Rasagiline mesylate, citric acid monohydrate to purified water under constant stirring.
  • step iii) Binder solution of step iii) was added to step ii) in RMG to obtain
  • step iv) Granules of step iv) were dried at 60°C inlet temperature to get the desired LOD.
  • step i) Mannitol and Pregelatinized starch were weighed and passed through #40 sieve.
  • Sifted material of step i) were mixed in RMG for 10 minutes at slow speed.
  • Binder solution was prepared by adding Rasagiline mesylate, hydroxy propyl ⁇ -cyclodextrin to purified water under constant stirring.
  • step iii) Binder solution of step iii) was added to step ii) in RMG to obtain granules.
  • Granules of step iv) were dried at 60°C inlet temperature to get the desired LOD.
  • Maize starch, colloidal silicon dioxide and talc were sifted through #40 sieve and blended with the granules of step v) for 10 minutes at slow speed.
  • Table-4 Pharmaceutical composition of the invention (Rasagiline mesylate Tablet):
  • step i) Sifted material of step i) were mixed in RMG for 10 minutes at slow speed.
  • Binder solution was prepared by adding Rasagiline mesylate, citric acid monohydrate to purified water under constant stirring.
  • step iv) Binder solution of step iii) was added to step ii) in RMG.
  • Granules of step iv) were dried at 60°C inlet temperature to get the desired LOD.
  • Colloidal silicon dioxide and talc were sifted through #40 sieve and blended with the granules of step v) for 10 minutes at slow speed.
  • step i) Mannitol and Pregelatinized starch were weighed and passed through #40 sieve.
  • Sifted material of step i) were mixed in RMG for 10 minutes at slow speed.
  • Binder solution was prepared by adding Rasagiline mesylate, ⁇ -cyclodextrin to purified water under constant stirring.
  • step iii) Binder solution of step iii) was added to step ii) in RMG to obtain granules.
  • Granules of step iv) were dried at 60°C inlet temperature to get the desired LOD.
  • Maize starch, colloidal silicon dioxide and talc were sifted through #40 sieve and blended with the granules of step v) for 10 minutes at slow speed.
  • Table-6 Pharmaceutical composition of the invention (Rasagiline mesylate Tablet):
  • step i) Sifted material of step i) were mixed in RMG for 10 minutes at slow speed.
  • Binder solution was prepared by adding citric acid monohydrate to purified water under constant stirring.
  • step iii) Binder solution of step iii) was added to step ii) in RMG to obtain granules.
  • Granules of step iv) were dried at 60°C inlet temperature to get the desired LOD.
  • Colloidal silicon dioxide and talc were sifted through #40 sieve and blended with the granules of step v) for 10 minutes at slow speed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques orales stables contenant de la rasagiline ou un sel pharmaceutiquement acceptable de celle-ci et au moins un ou plusieurs antioxydants pharmaceutiquement acceptables, ladite composition étant exempte de polyols. La présente invention concerne également des procédés de préparation des compositions de la présente invention.
PCT/IB2013/053060 2012-05-07 2013-04-18 Compositions pharmaceutiques contenant de la rasagiline WO2013168032A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1395/MUM/2012 2012-05-07
IN1395MU2012 2012-05-07

Publications (1)

Publication Number Publication Date
WO2013168032A1 true WO2013168032A1 (fr) 2013-11-14

Family

ID=49550245

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/053060 WO2013168032A1 (fr) 2012-05-07 2013-04-18 Compositions pharmaceutiques contenant de la rasagiline

Country Status (1)

Country Link
WO (1) WO2013168032A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114469902A (zh) * 2020-10-23 2022-05-13 上海上药中西制药有限公司 雷沙吉兰或其药用盐舌下膜剂及其制备方法、应用
EP4035654A1 (fr) 2021-01-30 2022-08-03 Intas Pharmaceuticals Limited Forme de dosage solide pharmaceutique orodispersible de rasagiline
WO2022162612A1 (fr) 2021-01-30 2022-08-04 Intas Pharmaceuticals Ltd. Forme posologique pharmaceutique solide orodispersible de rasagiline

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892233A1 (fr) * 2006-08-18 2008-02-27 Ratiopharm GmbH De nouveaux sels de la substance active rasagiline
WO2009147681A1 (fr) * 2008-06-06 2009-12-10 Pharma Two B Ltd. Compositions pharmaceutiques pour le traitement de la maladie de parkinson
CA2777532A1 (fr) * 2009-10-29 2011-05-05 Chongqing Pharmaceutical Research Institute Co., Ltd. Composition stable de rasagiline
WO2012001594A1 (fr) * 2010-06-30 2012-01-05 Koninklijke Philips Electronics N.V. Visualisation d'images de volumes de tomodensitomètre médical

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892233A1 (fr) * 2006-08-18 2008-02-27 Ratiopharm GmbH De nouveaux sels de la substance active rasagiline
WO2009147681A1 (fr) * 2008-06-06 2009-12-10 Pharma Two B Ltd. Compositions pharmaceutiques pour le traitement de la maladie de parkinson
CA2777532A1 (fr) * 2009-10-29 2011-05-05 Chongqing Pharmaceutical Research Institute Co., Ltd. Composition stable de rasagiline
WO2012001594A1 (fr) * 2010-06-30 2012-01-05 Koninklijke Philips Electronics N.V. Visualisation d'images de volumes de tomodensitomètre médical

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114469902A (zh) * 2020-10-23 2022-05-13 上海上药中西制药有限公司 雷沙吉兰或其药用盐舌下膜剂及其制备方法、应用
EP4035654A1 (fr) 2021-01-30 2022-08-03 Intas Pharmaceuticals Limited Forme de dosage solide pharmaceutique orodispersible de rasagiline
WO2022162612A1 (fr) 2021-01-30 2022-08-04 Intas Pharmaceuticals Ltd. Forme posologique pharmaceutique solide orodispersible de rasagiline

Similar Documents

Publication Publication Date Title
US20210093575A1 (en) Immediate release formulations and dosage forms of gamma-hydroxybutyrate
AU2010352575C1 (en) Immediate release formulations and dosage forms of gamma-hydroxybutyrate
CN107530348B (zh) 一种含有jak激酶抑制剂或其可药用盐的药物组合物
US20100112056A1 (en) Immediate release dosage forms of sodium oxybate
US8022104B2 (en) Formulations of ladostigil tartrate
WO2011010324A1 (fr) Compositions pharmaceutiques orales stables comprenant de la rasagiline et procédé
WO2013168032A1 (fr) Compositions pharmaceutiques contenant de la rasagiline
JP6401270B2 (ja) 徐放性固体経口組成物
US20100086590A1 (en) Novel stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
US20080221079A1 (en) Pharmaceutical composition of quetiapine fumarate
US20090298944A1 (en) Pharmaceutical composition
WO2020148219A1 (fr) Procédé de fabrication de composition pharmaceutique comprenant du néfopam et de l'acétaminophène, et composition pharmaceutique ainsi obtenue
US10722469B2 (en) Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof
US9271951B2 (en) Levothyroxine formulation with acacia
CA2535529A1 (fr) Sels de phenylephrine tannate, pyrilamine tannate, et dextromethorphan tannate utilises dans des compositions pharmaceutiques
US20220257611A1 (en) A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby
WO2010010367A1 (fr) Composition pharmaceutique solide contenant de l'exémestane
EP3079672B1 (fr) Composition pharmaceutique comprenant un sel pharmaceutiquement acceptable de rasagiline
US20140179784A1 (en) Levothyroxine formulation with carrageenan
WO2015158463A1 (fr) Formes galéniques pharmaceutiques stables comprenant de la lévothyroxine sodique
WO2022058044A1 (fr) Forme posologique solide comprenant de la sitagliptine et son procédé de préparation
US20220175774A1 (en) Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor
WO2022219652A1 (fr) Nouvelles formulations pharmaceutiques sublinguales pour l'évérolimus
MX2012010659A (es) Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales.
WO2017114597A1 (fr) Formes pharmaceutiques comprenant du ((cis)-n-(4-(diméthylamino) -1,4-diphénylcyclohexyl)-n-méthylcinnamamide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13788622

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13788622

Country of ref document: EP

Kind code of ref document: A1